T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer.
TILs
immunohistochemistry
vulvar squamous cell cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Aug 2022
31 Aug 2022
Historique:
received:
19
06
2022
revised:
25
08
2022
accepted:
25
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Background: Although quantification of tumor infiltrating lymphocytes (TILs) has become of increasing interest in immuno-oncology, only little is known about TILs infiltration in the tumor microenvironment and its predictive value in vulvar cancer. Methods: Immunohistochemistry and automated digital image analysis was applied to measure the densities of CD3+ (DAKO, #IR503) and CD8+ (DAKO, #IR623) TILs at the invasive margin and in the center of 530 vulvar squamous cell cancers. Results: An elevated density of CD3+ T-cell at the invasive margin was significantly associated with low tumor stage (p = 0.0012) and prolonged survival (overall survival [OS] p = 0.0027, progression free survival [PFS] p = 0.024) and was independent from tumor stage, nodal stage, grade, and HPV-status in multivariate analysis (p < 0.05). The prognostic impact of CD3+ cells in the center of the tumor was weaker compared to the invasive margin (OS p = 0.046, PFS p = 0.031) and lacking for CD8+ T-cell densities at any location (p ≥ 0.14 each). Unsupervised clustering of CD3+ and CD8+ T-cell densities identified three major subgroups corresponding to the immune desert (137 patients), immune excluded (220 patients) and immune inflamed phenotypes (133 patients). Survival analysis revealed a particular poor prognosis for the immune desert phenotype for OS (p = 0.0071) and PFS (p = 0.0027). Conclusion: Our data demonstrate a high prognostic value of CD3+ T-cells at the invasive margin and immune phenotypes in vulvar squamous cell cancer.
Identifiants
pubmed: 36077784
pii: cancers14174246
doi: 10.3390/cancers14174246
pmc: PMC9454842
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
World J Gastroenterol. 2009 Dec 21;15(47):5898-906
pubmed: 20014453
Int J Gynecol Cancer. 2011 May;21(4):717-21
pubmed: 21543933
Int J Cancer. 2015 Feb 15;136(4):E85-94
pubmed: 25220265
Cancer Immunol Immunother. 2003 Jul;52(7):423-8
pubmed: 12695859
Front Immunol. 2019 Aug 02;10:1835
pubmed: 31428105
J Exp Clin Cancer Res. 2020 May 18;39(1):89
pubmed: 32423420
Br J Cancer. 2018 Jul;119(2):153-159
pubmed: 29955135
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Cancer Treat Res. 2020;180:173-195
pubmed: 32215870
Trends Immunol. 2018 Aug;39(8):632-643
pubmed: 29779848
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Front Med (Lausanne). 2021 Jan 27;8:622330
pubmed: 33585526
Immunity. 2011 Aug 26;35(2):161-8
pubmed: 21867926
Anticancer Res. 2005 May-Jun;25(3B):2027-31
pubmed: 16158940
Elife. 2018 Sep 04;7:
pubmed: 30179157
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
Clin Cancer Res. 2019 Jan 1;25(1):125-133
pubmed: 30301825
Cancer Manag Res. 2018 Jan 09;10:61-68
pubmed: 29386916
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
Int J Clin Exp Pathol. 2017 Sep 01;10(9):9846-9852
pubmed: 31966872
Int J Cancer. 2015 Feb 15;136(4):E95-106
pubmed: 25220367
Springerplus. 2016 Feb 18;5:125
pubmed: 26933624
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Adv Exp Med Biol. 2017;1036:19-31
pubmed: 29275462
Gynecol Oncol. 2012 Apr;125(1):186-93
pubmed: 22155674
BMC Cancer. 2020 Aug 31;20(1):823
pubmed: 32867707
Breast Cancer Res. 2018 Feb 26;20(1):15
pubmed: 29482642
Immunol Rev. 2017 Mar;276(1):145-164
pubmed: 28258703
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Cell. 2018 Aug 9;174(4):968-981.e15
pubmed: 30078711
Front Immunol. 2018 May 03;9:978
pubmed: 29774034
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
Hum Vaccin Immunother. 2016 Jun 2;12(6):1352-6
pubmed: 26901390
Geburtshilfe Frauenheilkd. 2016 Oct;76(10):1035-1049
pubmed: 27765958
J Natl Cancer Inst. 2015 Jan 24;107(3):
pubmed: 25618900
Am J Reprod Immunol. 2020 Jul;84(1):e13244
pubmed: 32294293
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Cancer Immunol Immunother. 2014 Mar;63(3):297-303
pubmed: 24368339
Gynecol Oncol. 2017 May;145(2):298-304
pubmed: 28236455
Dis Markers. 2019 May 2;2019:2532518
pubmed: 31191745
J Immunother Cancer. 2019 Sep 3;7(1):236
pubmed: 31481117
Oncotarget. 2017 Jul 11;8(28):46204-46210
pubmed: 28515351
Mod Pathol. 2019 Apr;32(4):576-584
pubmed: 30401949
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
Virchows Arch. 2020 Jul;477(1):93-102
pubmed: 31993774
Semin Oncol. 2015 Aug;42(4):663-71
pubmed: 26320069
Cancer Immunol Res. 2018 Oct;6(10):1122-1128
pubmed: 30279188
Cancer Med. 2020 Nov;9(22):8333-8344
pubmed: 33047888
J Immunol Res. 2017;2017:6940546
pubmed: 29376081
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
J Clin Oncol. 2019 Nov 1;37(31):2825-2834
pubmed: 31487218
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023